Adaptimmune Therapeutics PLC Sponsored ADR Stock

$0.98

4.29% yesterday

Nasdaq, Sep 27, 10:00 pm CET

ISIN

US00653A1079

Symbol

ADAP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Adaptimmune Therapeutics PLC Sponsored ADR Stock price

$0.98

-0.49 33.52% 5Y

Nasdaq, Closing price Fri, Sep 27 2024

+0.04 4.29%

ISIN

US00653A1079

Symbol

ADAP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$239.59m
Enterprise Value	$72.15m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	0.51
P/S ratio (TTM) P/S ratio	1.69
P/B ratio (TTM) P/B ratio	2.49
Revenue growth (TTM) Revenue growth	98.71%
Revenue (TTM) Revenue	$141.56m
EBIT (operating result TTM) EBIT	$-90.73m
Free Cash Flow (TTM) Free Cash Flow	$-46.05m
Cash position	$214.79m
EPS (TTM) EPS	$-0.35
P/E forward	negative
P/S forward	1.59
EV/Sales forward	0.48
Short interest	4.00%

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Get Started for Free Today

Adaptimmune Therapeutics PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Adaptimmune Therapeutics PLC Sponsored ADR forecast:

7x Buy

70%

2x Hold

20%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Adaptimmune Therapeutics PLC Sponsored ADR forecast:

Buy

70%

Hold

20%

Sell

10%

Analyst Estimates with Stock Price Targets

Financial data from Adaptimmune Therapeutics PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	142 142	99% 99% 100%
- Direct Costs	11 11	- 8%
Gross Profit	130 130	- 92%
- Selling and Administrative Expenses	49 49	13% 13% 35%
- Research and Development Expense	160 160	26% 26% 113%
EBITDA	-79 -79	34% 34% -56%
- Depreciation and Amortization	11 11	61% 61% 8%
EBIT (Operating Income) EBIT	-91 -91	28% 28% -64%
Net Profit	-73 -73	20% 20% -51%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Adaptimmune Therapeutics PLC Sponsored ADR Stock News

Neutral

Seeking Alpha

●

about 2 months ago

Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript

Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ET Company Participants Dan Od-Cohen - Investor Relations Adrian Rawcliffe - Chief Executive Officer Cintia Piccina - Chief Commercial Officer Joanna Brewer - Chief Scientific Officer Dennis Williams - Senior Vice President, Late Stage Development John Lunger - Chief Patient Supply Officer Ellio...

Positive

Reuters

●

about 2 months ago

US FDA approves Adaptimmune's gene therapy for rare type of cancer

The U.S. Food and Drug Administration said on Friday it has approved Adaptimmune's first-of-its-kind gene therapy to treat adult patients with a rare type of cancer that affects soft tissues who have received prior chemotherapy.

Neutral

Business Wire

●

about 2 months ago

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

PHILADELPHIA & OXFORD, England--(BUSINESS WIRE)--Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA® (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior ...

More Adaptimmune Therapeutics PLC Sponsored ADR News

Company Profile

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Head office	United Kingdom
CEO	Adrian Rawcliffe
Employees	449
Founded	2008
Website	www.adaptimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now